2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?

Eli Lilly has seized the lead in the GLP-1 market on the strength of tirzepatide—$24.8 billion in revenue in the first nine months of 2025—and a pipeline that includes oral orforglipron (phase 3 complete) and triple-agonist retatrutide (phase 3), positioning it to sustain rapid growth; its shares, while trading at a rich forward P/E of ~32, reflect superior revenue and earnings momentum. Novo Nordisk, whose semaglutide franchise has lost share (49.3% vs 55.7% a year earlier) and faced guidance revisions, is countering with label expansions (including metabolic dysfunction‑associated steatohepatitis), potential oral semaglutide, new agonists, and aggressive pricing (Wegovy/Ozempic at $349/month) to blunt compounding competition and capture cash-pay patients. For investors, Lilly looks like the growth leader worth its premium, while Novo Nordisk represents a lower‑valued, pipeline-rich alternative that could regain competitiveness as the obesity/weight‑loss market expands.

Analysis

Eli Lilly has established clear leadership in the GLP-1 market driven by tirzepatide, which generated $24.8 billion in revenue through the first nine months of 2025 and is now described as the world’s best-selling drug; tirzepatide has cannibalized Trulicity and shows efficacy across diabetes, obesity and sleep apnea. Lilly’s pipeline reinforces this lead: phase 3-complete oral orforglipron could become one of the first oral GLP-1s for weight management and retatrutide (a GLP-1/GIP/glucagon triple agonist) is in phase 3, enhancing its multi-product growth thesis. Novo Nordisk has ceded share (49.3% vs 55.7% a year earlier) and revised guidance amid slower sales and compounding pharmacy competition, but it is fighting back with label expansions (including metabolic dysfunction-associated steatohepatitis), a potential oral semaglutide, a triple agonist and the phase-3 dual agonist amycretin, plus aggressive cash pricing at $349/month for Wegovy/Ozempic to reach uninsured patients. Valuation contrasts matter: Lilly trades at ~32x forward earnings versus Novo Nordisk at ~12x and a healthcare average of 18.1; the article argues Lilly’s premium is justified by faster revenue and earnings growth, while Novo remains a lower-priced, pipeline-rich alternative and a potential rebound candidate if its recent initiatives restore share.

Key Decisions for Investors

• Consider increasing exposure to Eli Lilly to capture tirzepatide-driven growth, but size new positions with awareness of its ~32x forward P/E to manage valuation risk
• Monitor near-term catalysts (regulatory outcomes for oral orforglipron and retatrutide phase 3 readouts) and treat positive trial approvals as conviction points to add, negative surprises as triggers to trim
• Evaluate Novo Nordisk as a selectively attractive, lower-valuation alternative (roughly 12x forward earnings) and consider adding on evidence of stabilizing market share, successful oral semaglutide approval, or sustained uptake from the $349/month pricing strategy
• Hedge or take partial profits if market-share trends accelerate toward Lilly beyond current expectations, and set stop-loss or re-assessment triggers on further guidance revisions, material pipeline setbacks, or intensified pricing competition from compounding pharmacies